Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Labopharm requests FDA meeting on tramadol NDA

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Labopharm is requesting another meeting with FDA to discuss the NDA for its once-daily formulation of tramadol. "Should Labopharm and the agency fail to mutually agree on a path forward toward final regulatory approval, or should the FDA not grant the meeting within the next 30 days, Labopharm plans to appeal the FDA's current decision through the … formal dispute resolution process," the company announces Sept. 24. Labopharm's tramadol has received two "approvable" letters - in September 2006 and May 2007 (1Pharmaceutical Approvals Monthly, June 2007, In Brief). So far the company has responded with additional data analyses. In June, Labopharm indicated that the problems have involved statistical analysis issues, and that if the existing data did not satisfy the statistical requirements the firm would have to generate new data in an additional Phase III trial. Formal dispute resolution cannot be initiated while an application is under review...

You may also be interested in...

FDA rejects Labopharm’s tramadol appeal

Labopharm will persist in pursuing FDA's dispute resolution process with an appeal to the next supervisory level in the coming weeks, the company says after the agency rejected an appeal seeking approval of its once-daily tramadol NDA based on existing data. FDA responded to the appeal but did not overturn its May "approvable" decision, the company announces Nov. 21. Labopharm entered FDA's formal dispute resolution process in October after receiving two approvable letters for its once-daily tramadol; the agency asserted that the NDA's statistical method did not address missing information related to subjects who dropped out of the trials (1Pharmaceutical Approvals Monthly, October 2007, p. 32). In a meeting after the second letter, FDA indicated that an additional Phase III trial might be necessary to meet statistical requirements. Analysis of missing data from dropouts has also emerged as an issue in the review of Cipher's once-daily tramadol formulation, CIP-tramadol ER, which also received an approvable letter in May...

Labopharm once-daily tramadol "approvable" again

Labopharm received a second "approvable" letter May 30 for the NDA for its once-daily formulation of tramadol, the company said May 31. The new letter is FDA's answer to the December complete response the company submitted to satisfy the initial "approvable" letter it received in September (1Pharmaceutical Approvals Monthly January 2007, In Brief). Labopharm says it will discuss an "appropriate path forward" with FDA, but that it also may proceed with the Formal Dispute Resolution process it initiated in December at the same time it was responding to the September letter. Cipher's competing extended-release tramadol NDA also received an "approvable" letter in May (2Pharmaceutical Approvals Monthly May 2007, In Brief)...

Perjeta Among Biosimilar Targets As Viatris Insists It Can ‘Do A Lot More’

At Viatris’ inaugural investor day, management spoke at length about the company’s ambitions for biosimilars, underlining that the company currently had no plans to expand its manufacturing footprint at the present time.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts